Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Tramadol: From Its Origins to Its Final Exit — A Complete Journey Through the Body
Mohamad-Ali Salloum, PharmD • March 7, 2026
Share
1. Where It All Began — The History
From Laboratory Design to Market
Tramadol didn’t come from a plant or a century‑old apothecary recipe. It was engineered. German pharmaceutical company Grünenthal first synthesized tramadol in the 1960s, with its preparation formally published in 1965, and eventually launched it in 1977 under the brand name Tramal.
It entered the U.S. market in 1995 as Ultram, originally not a controlled substance. But as misuse reports increased, it was later moved into Schedule IV due to its abuse potential and opioid‑like effects.
At its core, tramadol was designed to be a “hybrid analgesic”—a medication that combines weak opioid activity with monoamine modulation (serotonin and norepinephrine). This duality is the key to understanding everything that happens next.
2. The Patient Swallows It — The Start of the Journey
Absorption — Entering the System
A patient takes an oral tramadol tablet for moderate pain. Now the real story begins.
Absorption: Tramadol is rapidly and almost completely absorbed, though its oral bioavailability (≈65–75%) is reduced by first‑pass metabolism in the liver. Peak levels usually occur within 1–2 hours.
Once in the bloodstream, only about 20% binds to plasma proteins, leaving plenty available for activity. It distributes widely throughout the body and crosses the blood–brain barrier, which is essential for its analgesic effects.
3. First‑Pass Metabolism — The Liver’s Critical Decision
Two Dominant Pathways
CYP2D6 → O‑desmethyltramadol (M1)
This is the active opioid metabolite. It binds much more strongly to μ‑opioid receptors than the parent drug and is more potent at producing analgesia.
CYP3A4 / CYP2B6 → N‑desmethyltramadol (M2)
Much less pharmacologically important.
Genetic impact (CYP2D6):
- A patient who is a poor metabolizer produces less M1 → weaker opioid effect.
- An ultrarapid metabolizer produces more M1 → stronger effects but higher risk of opioid toxicity.
So even before tramadol reaches its site of action, two patients taking the same dose may experience very different results.
4. Reaching the Brain — Where Pharmacodynamics Come Alive
Mechanism of Action (MOA)
A) Opioid Pathway — Powered by M1
M1 binds to μ‑opioid receptors in the brain and spinal cord. This reduces pain signal transmission and produces classic opioid analgesia.
B) Monoaminergic Pathway — Driven by Parent Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake. This strengthens descending inhibitory pain pathways in the spinal cord, enhancing analgesia.
- Dampening pain signals traveling upward
- Strengthening the brain’s own pain‑suppressing pathways
This is why tramadol can help in certain neuropathic pain profiles where pure opioids fail.
5. The Clinical Effect — What the Patient Feels
Onset and Duration
Pain relief begins at about 1 hour after ingestion and lasts around 6 hours for immediate‑release formulations. This depends not just on absorption but also on how efficiently the patient converts tramadol into its active M1 metabolite.
6. Side Effects — The Direct Consequences of Its Mechanisms
Key Risks and Mechanisms
A) Serotonin Syndrome
Because tramadol increases serotonin levels, using it with SSRIs, SNRIs, MAOIs, or CYP2D6 inhibitors can dangerously elevate serotonin.
Symptoms:
agitation, clonus, hyperreflexia, sweating, fever.
Mechanism:
excess serotonergic activity.
B) Seizures
Tramadol lowers the seizure threshold, especially at high doses or in combination with other pro‑convulsant drugs.
Mechanism:
monoaminergic stimulation + metabolite accumulation.
C) Respiratory Depression
Usually milder than strong opioids, but can be severe in:
- Ultrarapid CYP2D6 metabolizers
- Overdose
- Combined use with sedatives
D) Typical Opioid Effects
Nausea, vomiting, constipation, dizziness, somnolence, sweating, pruritus.
Mechanism:
μ‑receptor activation + central effects.
E) Pediatric Risks
Children <12 years — contraindicated.
Post‑tonsillectomy/adenoidectomy <18 years — avoid.
Reason:
genetically driven excessive formation of M1 → life‑threatening respiratory depression.
7. The Final Chapter — Excretion
How It Leaves the Body
After doing its job, tramadol leaves the body mainly through the kidneys.
- Elimination half‑life:
- Parent tramadol: ~6 hours
- M1 metabolite: ~6–7.5 hours
Renal impairment slows clearance, requiring dose adjustments for IR formulations and avoidance of ER in severe cases. Ultimately, the metabolites are excreted in the urine, completing the medication’s journey.
Putting It All Together
A Unified View
- History: engineered to be part opioid, part monoamine‑modulating analgesic.
- Absorption & PK: efficiently absorbed, heavily shaped by CYP2D6 genetics.
- Mechanism & PD: dual action — μ‑opioid + serotonin/norepinephrine reuptake inhibition.
- Side effects: predictable consequences of its mechanisms.
- Excretion: renal elimination determines how long it stays active.
This unified view helps pharmacy and medical students understand not just what tramadol does, but why it behaves the way it does inside the body.
1. Where It All Began — The History
From Laboratory Design to Market
Tramadol didn’t come from a plant or a century‑old apothecary recipe. It was engineered. German pharmaceutical company Grünenthal first synthesized tramadol in the 1960s, with its preparation formally published in 1965, and eventually launched it in 1977 under the brand name Tramal.
It entered the U.S. market in 1995 as Ultram, originally not a controlled substance. But as misuse reports increased, it was later moved into Schedule IV due to its abuse potential and opioid‑like effects.
At its core, tramadol was designed to be a “hybrid analgesic”—a medication that combines weak opioid activity with monoamine modulation (serotonin and norepinephrine). This duality is the key to understanding everything that happens next.
2. The Patient Swallows It — The Start of the Journey
Absorption — Entering the System
A patient takes an oral tramadol tablet for moderate pain. Now the real story begins.
Absorption: Tramadol is rapidly and almost completely absorbed, though its oral bioavailability (≈65–75%) is reduced by first‑pass metabolism in the liver. Peak levels usually occur within 1–2 hours.
Once in the bloodstream, only about 20% binds to plasma proteins, leaving plenty available for activity. It distributes widely throughout the body and crosses the blood–brain barrier, which is essential for its analgesic effects.
3. First‑Pass Metabolism — The Liver’s Critical Decision
Two Dominant Pathways
CYP2D6 → O‑desmethyltramadol (M1)
This is the active opioid metabolite. It binds much more strongly to μ‑opioid receptors than the parent drug and is more potent at producing analgesia.
CYP3A4 / CYP2B6 → N‑desmethyltramadol (M2)
Much less pharmacologically important.
Genetic impact (CYP2D6):
- A patient who is a poor metabolizer produces less M1 → weaker opioid effect.
- An ultrarapid metabolizer produces more M1 → stronger effects but higher risk of opioid toxicity.
So even before tramadol reaches its site of action, two patients taking the same dose may experience very different results.
4. Reaching the Brain — Where Pharmacodynamics Come Alive
Mechanism of Action (MOA)
A) Opioid Pathway — Powered by M1
M1 binds to μ‑opioid receptors in the brain and spinal cord. This reduces pain signal transmission and produces classic opioid analgesia.
B) Monoaminergic Pathway — Driven by Parent Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake. This strengthens descending inhibitory pain pathways in the spinal cord, enhancing analgesia.
- Dampening pain signals traveling upward
- Strengthening the brain’s own pain‑suppressing pathways
This is why tramadol can help in certain neuropathic pain profiles where pure opioids fail.
5. The Clinical Effect — What the Patient Feels
Onset and Duration
Pain relief begins at about 1 hour after ingestion and lasts around 6 hours for immediate‑release formulations. This depends not just on absorption but also on how efficiently the patient converts tramadol into its active M1 metabolite.
6. Side Effects — The Direct Consequences of Its Mechanisms
Key Risks and Mechanisms
A) Serotonin Syndrome
Because tramadol increases serotonin levels, using it with SSRIs, SNRIs, MAOIs, or CYP2D6 inhibitors can dangerously elevate serotonin.
Symptoms:
agitation, clonus, hyperreflexia, sweating, fever.
Mechanism:
excess serotonergic activity.
B) Seizures
Tramadol lowers the seizure threshold, especially at high doses or in combination with other pro‑convulsant drugs.
Mechanism:
monoaminergic stimulation + metabolite accumulation.
C) Respiratory Depression
Usually milder than strong opioids, but can be severe in:
- Ultrarapid CYP2D6 metabolizers
- Overdose
- Combined use with sedatives
D) Typical Opioid Effects
Nausea, vomiting, constipation, dizziness, somnolence, sweating, pruritus.
Mechanism:
μ‑receptor activation + central effects.
E) Pediatric Risks
Children <12 years — contraindicated.
Post‑tonsillectomy/adenoidectomy <18 years — avoid.
Reason:
genetically driven excessive formation of M1 → life‑threatening respiratory depression.
7. The Final Chapter — Excretion
How It Leaves the Body
After doing its job, tramadol leaves the body mainly through the kidneys.
- Elimination half‑life:
- Parent tramadol: ~6 hours
- M1 metabolite: ~6–7.5 hours
Renal impairment slows clearance, requiring dose adjustments for IR formulations and avoidance of ER in severe cases. Ultimately, the metabolites are excreted in the urine, completing the medication’s journey.
Putting It All Together
A Unified View
- History: engineered to be part opioid, part monoamine‑modulating analgesic.
- Absorption & PK: efficiently absorbed, heavily shaped by CYP2D6 genetics.
- Mechanism & PD: dual action — μ‑opioid + serotonin/norepinephrine reuptake inhibition.
- Side effects: predictable consequences of its mechanisms.
- Excretion: renal elimination determines how long it stays active.
References :
- American Chemical Society. Tramadol – Molecule of the Week Archive. December 16, 2014. [acs.org]
- DEA Diversion Control Division. Tramadol Drug & Chemical Evaluation Section Report. April 2025. [deadiversi....usdoj.gov]
- Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879‑923. [go.drugbank.com]
- Food and Drug Administration (FDA). ULTRAM® (tramadol hydrochloride) tablets label. 2004. [accessdata.fda.gov]
- Nickson C. Tramadol – CCC Pharmacology. Life in the Fast Lane; 2024. [litfl.com]
- DrugBank Online. Tramadol: Uses, Interactions, Mechanism of Action. DB00193. [go.drugbank.com]
- Food and Drug Administration (FDA). Tramadol Hydrochloride Tablets (DailyMed). 2023. [dailymed.nlm.nih.gov]
- Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries. 2015. [ncbi.nlm.nih.gov]
- Food and Drug Administration (FDA). Tramadol ER Capsules Label Information. 2010. [accessdata.fda.gov]
- EBM Consult. Mechanism for Tramadol‑Induced Serotonin Syndrome in Patients Taking SSRIs. 2017.
- Medsafe Pharmacovigilance. Serious Reactions with Tramadol: Seizures and Serotonin Syndrome. 2007.
- Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1–6.
- Medscape Reference. Ultram, ConZip (tramadol) dosing, indications, interactions. 2026.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
A thoughtful reflection on Declutter Your Mind, exploring mental clutter, awareness, negative thinking patterns, mindfulness, and practical habits for mental clarity.
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
A clear, evidence‑based guide to Ramadan fasting, explaining its metabolic, mental, and cardiometabolic benefits, plus practical nutrition, hydration, sleep, and medication strategies for healthy adults and high‑risk patients.
A practical guide to shifting from blaming “human error” to applying ICH GCP E6(R3) system‑level quality, Quality by Design, and risk‑based oversight to prevent repeat deviations in clinical trials.
Learn 5 Whys and Fishbone (Ishikawa) for Root Cause Analysis in clinical research, with practical examples and an interactive quiz—no fluff, just clarity.
A clear, practical guide to CAPA for Clinical Research Associates—covering corrective and preventive actions, real‑world scenarios, and an interactive quiz to reinforce learning.
Boost your health with a simple 30‑minute morning walk backed by science—better heart health, mood, sleep, and energy.
References: Gunes IB, Gunes A. Association Between Eyelid Twitching and Digital Screen Time, Uncorrected Refractive Error, Intraocular Pressure, and Blood Electrolyte Imbalances. Cureus . 2024;16(9):e69249. Available from: https://www.cureus.com/articles/291035-association-between-eyelid-twitching-and-digital-screen-time-uncorrected-refractive-error-intraocular-pressure-and-blood-electrolyte-imbalances Banik R, Miller NR. Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol . 2004;24(4):290–2. Available from: https://scholars.mssm.edu/en/publications/chronic-myokymia-limited-to-the-eyelid-is-a-benign-condition-2 Hallett M. Blepharospasm: recent advances. Neurology . 2002;59(11):1759–60. Available from: https://europepmc.org/abstract/MED/12434791 Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord . 2002;17(1):7–12. Available from: https://europepmc.org/article/MED/11835433 Zeppieri M, Ameer MA, Jahngir MU, Patel BC. Meige Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://europepmc.org/article/MED/30020730 Zhang Y, Adamec I, Habek M. Superior oblique myokymia: a meta-analysis. J Ophthalmol . 2018;2018:7290547. Available from: https://doi.org/10.1155/2018/7290547 Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev . 2020;11:CD004900. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004900.pub2/abstract Khalkhali M. Topiramate-induced persistent eyelid myokymia. Case Rep Psychiatry . 2016;2016:7901085. Available from: https://europepmc.org/articles/PMC4886081/